Published on 22/12/2025
Understanding Global Variability in SUSAR Definitions
Introduction: Why SUSAR Definitions Differ Across the Globe
Suspected Unexpected Serious Adverse Reactions (SUSARs) are a cornerstone of pharmacovigilance in clinical trials. Yet, despite harmonization attempts under ICH E2A and CIOMS, definitions and interpretations of SUSARs vary significantly across regulatory regions. This variability creates complexity for sponsors conducting multinational trials, where a single adverse event may be classified differently depending on the jurisdiction. Misclassification or inconsistent reporting can result in inspection findings, delayed approvals, or regulatory sanctions.
Understanding global differences is essential for compliance and efficient trial management. This tutorial explores how various authorities define SUSARs, the implications of variability, challenges faced by sponsors, case study examples, and best practices for harmonizing approaches across regions.
Core Elements of a SUSAR Definition
While terminology varies, most regulators agree on three defining criteria for a SUSAR:
- Serious: The event results in death, is life-threatening, requires hospitalization, causes disability, or is otherwise medically important.
- Unexpected: The nature or severity of the event is not consistent with the known safety profile in the Investigator’s Brochure (IB) or Summary of Product Characteristics (SmPC).
- Suspected relationship: A reasonable possibility exists that the investigational product (IP) caused the event.
Despite this common
Regional Regulatory Perspectives on SUSARs
Examples of differences across major regulatory regions include:
- FDA (US): Focuses on “reasonable possibility” of causality. Requires expedited reporting of any unexpected serious suspected adverse reaction, whether observed domestically or abroad, within 7 or 15 days.
- EMA (EU): Defines SUSARs with emphasis on comparison to the Reference Safety Information (RSI) in the IB. Requires electronic submission via EudraVigilance.
- MHRA (UK): Aligns with EU principles but requires parallel submissions to Research Ethics Committees.
- PMDA (Japan): Requires detailed causality justification and case narratives; timelines generally align with ICH but involve country-specific templates.
- DCGI (India): Requires SUSAR reporting to both regulators and institutional ethics committees, often within 14 days.
- Health Canada: Requires immediate notification of fatal/life-threatening SUSARs, with less prescriptive causality language compared to EMA.
These differences illustrate how a case classified as “serious unexpected adverse reaction” in the EU may not meet SUSAR criteria in the US, complicating global trial safety oversight.
Case Studies Illustrating Variability
Case Study 1 – Oncology Trial: A Grade 3 neutropenia case was classified as a SUSAR in the EU (not listed in RSI) but not in the US (considered within expected chemotherapy risks). Sponsors reconciled by reporting to both but annotating the classification difference in submissions.
Case Study 2 – Vaccine Trial: Myocarditis events were expedited as SUSARs in the EU but reported as “unanticipated problems” in the US. Ethics committees required plain-language summaries, adding to workload.
Case Study 3 – Cardiovascular Device Trial: Device-related adverse events overlapped with SUSAR reporting rules inconsistently across EU and Asian regions, requiring sponsor SOP adjustments.
Challenges Arising from Global Variability
Sponsors managing international trials face challenges including:
- Operational burden: Different forms, timelines, and submission portals across jurisdictions.
- Inconsistent causality judgments: What one authority deems “related” another may not.
- Database complexity: Reconciling definitions across pharmacovigilance and clinical data management systems.
- Inspection readiness: Regulators expect consistent justification for handling SUSARs across multiple regions.
These challenges are compounded in large-scale oncology or vaccine programs where SUSAR volume is high and reporting windows are short.
Best Practices for Managing SUSAR Variability
To manage differences across jurisdictions, sponsors should implement best practices such as:
- Develop global SOPs with annexes for country-specific SUSAR requirements.
- Use centralized pharmacovigilance databases that flag discrepancies in classification.
- Maintain dual reporting strategies where regulatory definitions diverge.
- Provide training modules for investigators on regional differences in SUSAR definitions.
- Engage regulatory intelligence teams to track evolving requirements in real time.
For example, a sponsor running a global oncology trial created a harmonized template that included FDA, EMA, and MHRA criteria side-by-side, helping investigators classify SUSARs consistently across sites.
Regulatory Implications of Poor Harmonization
Failure to address variability in SUSAR definitions can lead to:
- Regulatory findings: Authorities may cite sponsors for inconsistent or delayed SUSAR reporting.
- Increased risk to participants: Delayed recognition of emerging safety issues undermines trial oversight.
- Operational inefficiency: Redundant or conflicting submissions increase workload and costs.
- Delayed approvals: Authorities may withhold trial continuation or marketing authorizations pending safety clarification.
Key Takeaways
SUSAR definitions are broadly aligned across regulators but differ in interpretation and operational application. To ensure compliance in global trials, sponsors must:
- Understand regional differences in SUSAR criteria and timelines.
- Adopt global SOPs that integrate country-specific nuances.
- Reconcile classification discrepancies across systems and submissions.
- Train investigators and pharmacovigilance staff on variable definitions.
By proactively managing variability, trial teams can ensure accurate and timely SUSAR reporting worldwide, strengthen pharmacovigilance, and protect participants across jurisdictions.